PMID- 21323513
OWN - NLM
STAT- MEDLINE
DCOM- 20110714
LR  - 20190116
IS  - 1029-2403 (Electronic)
IS  - 1026-8022 (Linking)
VI  - 52
IP  - 4
DP  - 2011 Apr
TI  - Predictive value of TP53 fluorescence in situ hybridization in cytogenetic 
      subgroups of acute myeloid leukemia.
PG  - 642-7
LID - 10.3109/10428194.2010.551571 [doi]
AB  - Acute myeloid leukemia (AML) with a complex karyotype (CK) has frequent 
      alterations in TP53 and a very poor prognosis. We examined whether a prompt and 
      simple fluorescence in situ hybridization (FISH) analysis for 17p13 deletion at 
      diagnosis has a predictive value for response to therapy and overall survival in 
      subgroups of AML. In 15 patients with a normal karyotype the TP53 FISH analysis 
      was normal, whereas in 16 patients with CK 75% had only one copy of the TP53 
      allele. The deletion was also detected in 33% of six patients with monosomy or 
      partial monosomy of chromosome 5, 7, 9, or 12. This loss of TP53 correlated 
      significantly with a poor response to chemotherapy, and the median survival time 
      of these patients was shorter. TP53 FISH analysis carried out at diagnosis has a 
      predictive value with respect to chemotherapy response and can therefore 
      facilitate a rapid decision on treatment strategies.
FAU - Tavor, Sigal
AU  - Tavor S
AD  - Department of Hematology and Bone Marrow Transplantation, Tel-Aviv Sourasky 
      Medical Center, Israel. tavorsigal@yahoo.com
FAU - Rothman, Rachel
AU  - Rothman R
FAU - Golan, Tamar
AU  - Golan T
FAU - Voskoboinik, Nadia
AU  - Voskoboinik N
FAU - Katz, Ben-Zion
AU  - Katz BZ
FAU - Sarid, Nadav
AU  - Sarid N
FAU - Shomrat, Ruth
AU  - Shomrat R
FAU - Orr-Urtreger, Avi
AU  - Orr-Urtreger A
FAU - Naparstek, Elizabeth
AU  - Naparstek E
LA  - eng
PT  - Journal Article
DEP - 20110216
PL  - United States
TA  - Leuk Lymphoma
JT  - Leukemia & lymphoma
JID - 9007422
RN  - 0 (Antineoplastic Agents)
RN  - 0 (TP53 protein, human)
RN  - 0 (Tumor Suppressor Protein p53)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Agents/therapeutic use
MH  - Female
MH  - Gene Deletion
MH  - Humans
MH  - *In Situ Hybridization, Fluorescence
MH  - Karyotyping
MH  - Leukemia, Myeloid, Acute/*diagnosis/drug therapy/genetics
MH  - Male
MH  - Middle Aged
MH  - Predictive Value of Tests
MH  - Survival Analysis
MH  - Treatment Outcome
MH  - Tumor Suppressor Protein p53/genetics/*metabolism
EDAT- 2011/02/18 06:00
MHDA- 2011/07/16 06:00
CRDT- 2011/02/18 06:00
PHST- 2011/02/18 06:00 [entrez]
PHST- 2011/02/18 06:00 [pubmed]
PHST- 2011/07/16 06:00 [medline]
AID - 10.3109/10428194.2010.551571 [doi]
PST - ppublish
SO  - Leuk Lymphoma. 2011 Apr;52(4):642-7. doi: 10.3109/10428194.2010.551571. Epub 2011 
      Feb 16.